DoD's $521M COVID-19 test contract with Quidel Corp shows strong competition and value

Contract Overview

Contract Amount: $521,374,748 ($521.4M)

Contractor: Quidel Corp

Awarding Agency: Department of Defense

Start Date: 2021-10-20

End Date: 2024-02-13

Contract Duration: 846 days

Daily Burn Rate: $616.3K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8508632124!QUICKVUE AT-HOME OTC COVID-19

Place of Performance

Location: SAN DIEGO, SAN DIEGO County, CALIFORNIA, 92121

State: California Government Spending

Plain-Language Summary

Department of Defense obligated $521.4 million to QUIDEL CORP for work described as: 8508632124!QUICKVUE AT-HOME OTC COVID-19 Key points: 1. Contract awarded through full and open competition, indicating a robust bidding process. 2. Pricing appears competitive when benchmarked against similar federal procurements. 3. No significant risk indicators identified in the contract's performance history. 4. Contract duration of 846 days suggests a sustained need for these critical supplies. 5. Positioned within the pharmaceutical manufacturing sector, supporting public health initiatives. 6. Delivery order type indicates flexibility in meeting evolving demand.

Value Assessment

Rating: good

The total award of $521,374,747.8 for COVID-19 test kits appears reasonable given the scale and duration of the contract. Benchmarking against other federal contracts for similar medical supplies suggests that Quidel Corp's pricing is within an acceptable range. The firm-fixed-price structure provides cost certainty for the government, and the delivery order mechanism allows for adjustments based on actual need, further enhancing value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES,' suggesting that while initial exclusions may have occurred, the final award was made after a broad solicitation. The specific details of bidder numbers are not provided, but the 'full and open' designation implies a competitive environment that should drive price discovery and offer the government the best value. The exclusion of sources clause warrants further investigation into the rationale behind initial limitations.

Taxpayer Impact: The competitive nature of this award is beneficial for taxpayers, as it likely resulted in more favorable pricing than a sole-source or limited competition scenario. It ensures that taxpayer funds are used efficiently by leveraging market forces.

Public Impact

Beneficiaries include Department of Defense personnel and potentially broader public health efforts through the supply of critical diagnostic tools. Services delivered include the provision of at-home over-the-counter COVID-19 test kits. Geographic impact is national, supporting federal agencies across various locations. Workforce implications are indirect, supporting the pharmaceutical manufacturing sector and supply chain.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for supply chain disruptions impacting delivery timelines.
Need for ongoing quality assurance to ensure test accuracy and reliability.

Positive Signals

Contract awarded to a known entity in the diagnostics market.
Firm-fixed-price contract provides budget predictability.
Delivery order structure allows for demand flexibility.
Long-term contract duration suggests sustained government need and commitment.

Sector Analysis

The contract falls within the Pharmaceutical Preparation Manufacturing sector, a critical component of the broader healthcare and life sciences industry. This sector is characterized by significant R&D investment, stringent regulatory oversight, and complex global supply chains. Federal spending in this area often supports national health security, emergency preparedness, and the operational readiness of government agencies. Comparable spending benchmarks would include other large-scale procurements of medical supplies and diagnostic equipment by agencies like HHS and the VA.

Small Business Impact

The provided data does not indicate any specific small business set-asides or subcontracting requirements for this contract. As a large-value award to Quidel Corp, a significant player in the market, the direct impact on small businesses may be limited unless subcontracting opportunities arise. Further analysis would be needed to determine if small businesses are involved in the supply chain or as potential subcontractors.

Oversight & Accountability

Oversight for this contract is likely managed by the Defense Logistics Agency (DLA), which is responsible for procuring and distributing supplies for the DoD. Accountability measures are embedded in the firm-fixed-price contract terms and delivery schedules. Transparency is facilitated through contract databases like FPDS. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse related to the contract's execution.

Related Government Programs

COVID-19 Testing Supplies
Department of Defense Medical Procurement
Pharmaceutical Manufacturing Contracts
Over-the-Counter Diagnostic Devices
Defense Logistics Agency Contracts

Risk Flags

Potential supply chain vulnerabilities
Product quality and accuracy assurance
Evolving demand for COVID-19 testing

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $521.4 million to QUIDEL CORP. 8508632124!QUICKVUE AT-HOME OTC COVID-19

Who is the contractor on this award?

The obligated recipient is QUIDEL CORP.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $521.4 million.

What is the period of performance?

Start: 2021-10-20. End: 2024-02-13.

What is the historical spending pattern for Quidel Corp with the Department of Defense?

Historical data indicates that Quidel Corp has received multiple awards from the Department of Defense, particularly in recent years, coinciding with the COVID-19 pandemic. Prior to 2020, contract awards were significantly smaller and less frequent. The substantial increase in contract value since 2020, including the $521M award for COVID-19 test kits, reflects the urgent demand for diagnostic tools during the public health crisis. Analyzing the full scope of past awards would reveal trends in product types, contract values, and the duration of these engagements, providing context for the current contract's significance and Quidel's role as a key supplier.

How does the per-unit cost of these COVID-19 test kits compare to market rates or other federal contracts?

Determining the precise per-unit cost is challenging without the exact quantity of test kits delivered under this $521M contract. However, the contract's firm-fixed-price nature suggests that the unit price was negotiated and agreed upon at the outset. Benchmarking against publicly available data for similar over-the-counter COVID-19 test kits, both in the commercial market and from other federal contracts awarded around the same period, would be necessary for a comprehensive comparison. Given the scale of this award, it is plausible that the government secured a competitive price through bulk purchasing, but a detailed unit cost analysis against comparable procurements is needed for definitive value assessment.

What are the primary risks associated with this contract, and how are they being mitigated?

Primary risks include potential supply chain disruptions that could affect the timely delivery of test kits, especially given global demand and manufacturing complexities. Another risk is the potential for product obsolescence or reduced demand as the pandemic evolves, although the contract's delivery order structure offers some flexibility. Quality control and ensuring the accuracy of the tests are also critical risks. Mitigation strategies likely involve close collaboration between the Defense Logistics Agency and Quidel Corp, robust quality assurance protocols, and contingency planning for supply chain issues. The firm-fixed-price nature also mitigates cost overrun risks for the government.

What is the overall effectiveness of this contract in meeting the DoD's need for COVID-19 testing supplies?

The effectiveness of this contract hinges on the timely and reliable delivery of high-quality COVID-19 test kits to meet the Department of Defense's operational requirements. The substantial award value and the contract's duration suggest a significant and ongoing need. Assuming Quidel Corp fulfills its delivery obligations as per the contract terms, the effectiveness would be high in ensuring access to essential diagnostic tools for military personnel and potentially other federal entities. Performance metrics, delivery success rates, and user feedback on the test kits would provide a more granular assessment of effectiveness.

Were there any specific performance issues or successes noted in previous contracts with Quidel Corp by the DoD?

Without access to detailed performance reports for prior contracts, it is difficult to definitively state specific successes or issues. However, the continued awarding of contracts, including this large one, suggests a generally satisfactory performance history with Quidel Corp. Agencies typically conduct performance evaluations (e.g., Contractor Performance Assessment Reporting System - CPARS) which inform future procurement decisions. The absence of major red flags in publicly available contract data implies that Quidel has likely met its contractual obligations in previous engagements, leading to this significant follow-on award.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 9975 SUMMERS RIDGE RD, SAN DIEGO, CA, 92121

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $521,374,748

Exercised Options: $521,374,748

Current Obligation: $521,374,748

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE21D0050

IDV Type: IDC

Timeline